G. Paul Bosse III has served as the President and Chief Executive Officer of Charleston Laboratories, Inc. since 2007. Mr. Bosse is the inventor of Charleston’s novel product concepts, drug delivery platforms, and patent filings, as well as the Company’s original founding member.
With 15 years of sales, marketing, and executive management experience in the pharmaceutical industry, and as a former founder of a small, privately held pharmaceutical company, Mr. Bosse brings a wealth of experience managing strategic partnerships to Charleston.
A natural leader with a distinctive energy, Mr. Bosse’s determination and drive won’t allow him to simply meet goals—but rather exceed expectations and milestones in everything he does. It’s this mindset that makes Mr. Bosse ideally suited to leading Charleston forward as an ethically responsible pharmaceutical company, committed to change in the face of the current opioid crisis.
Key Accomplishments
Dr. Bernard P. Schachtel helped to found Charleston Laboratories, Inc. in 2007 and currently serves as its Chief Scientific Officer and Member of the Scientific Advisory Board. Dr. Schachtel serves as the President of Schachtel Research Company (SRC), has over 30 years’ experience in analgesic research, and has served as Consultant to the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration.
Throughout his career, Dr. Schachtel has held academic appointments at McGill University, the University of Pittsburgh, and Yale University, where he is a Lecturer in Epidemiology and Public Health. After residency and a fellowship at the National Institutes of Health, he was a Robert Wood Johnson Clinical Scholar in the Departments of Medicine and Epidemiology and Public Health at the Yale University School of Medicine. Dr. Schachtel was also a leading developer of the pain measurement scales, which assess and compare the efficacy of analgesics.
Key Accomplishments
George A. Scott joined Charleston Laboratories in January 2016 after serving as outside counsel for the company since 2014. Mr. Scott serves as the company’s Chief Legal Officer and General Counsel. Mr. Scott manages and oversees all of the legal affairs for the company and its affiliates, including all issues related to partnerships and alliances, mergers and acquisitions, labor and employment, corporate governance, compliance, litigation, and management of risk for Charleston. Prior to joining the company, Mr. Scott spent several years with large global law firms, most recently with Greenberg Traurig. Mr. Scott brings over a decade of legal experience representing public and private companies, including numerous emerging pharmaceutical and life-science companies. Prior to his legal career, he worked in investment banking for one of the largest investment banks in the world. Mr. Scott holds a BS from Syracuse University, an MBA from Wagner College, and a JD from Charlotte School of Law.
Key Accomplishments
John F. Ameling serves as Vice President of Regulatory Affairs at Charleston Laboratories, Inc. With over 32 years of experience working in regulatory affairs, Mr. Ameling has successfully executed 5 NDAs and submitted over 40 INDs to the FDA. Mr. Ameling has coordinated over 125 meetings with the FDA, presented to FDA Advisory Committees, been an “expert witness” in several lawsuits and testified before the US Congress. As Charleston’s Vice President of Regulatory Affairs, Mr. Ameling’s duties include leading all communications with the FDA, directing regulatory strategy for the company’s novel pipeline of products, and managing contract manufacturing.
Key Accomplishments
Dr. William J. Kozarek serves as Vice President of Product Development at Charleston Laboratories, Inc. He has 29 years of industrial experience and nine years of consulting to the pharmaceutical industry. Dr. Kozarek has extensive experience in Rx and OTC drugs and has played key roles in the Rx to OTC switch of Prilosec®, Aleve® and Femstat®.
Key Accomplishments